POS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysis
Loading...
Identifiers
Publication date
Authors
Rossing, Peter
Agarwal, Rajiv L.
Anker, Stefan D.
Filippatos, Gerasimos S.
Pitt, Bertram
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD progression despite current therapies, which tends to worsen with more advanced CKD. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, decreased the risk of kidney and cardiovascular (CV) outcomes in phase III trials for patients with CKD and T2D. Combining finerenone with other CKD in T2D therapies, such as sodium-glucose co-transporter-2 inhibitors (SGLT-2is) is of interest, but more data are needed. FI nerenone in chronic kiD ney diseasE and type 2 diabetes: Combined FIDEL IO-DKD and FI GARO-DKD T rial programme analY sis (FIDELITY) aims to evaluate the effects of finerenone on composite kidney and CV endpoints in varying stages of CKD (defined by estimated glomerular filtration rate [eGFR] and urine albumin-to-creatinine ratio [UACR]). The benefits of combining finerenone with SGLT-2is was also evaluated.
Description
UNESCO Subjects
Keywords
Bibliographic reference
Rossing, P., Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Joseph, A., Gebel, M., Kolkhof, P., Nowack, C., & Bakris, G. L. (2022). POS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysis. Kidney International Reports, 7(2), S157-S158. https://doi.org/10.1016/j.ekir.2022.01.371